|

JS212 Clinical Trials

2 actively recruiting trials

Pipeline

Phase 2: 2

Top Sponsors

  • Shanghai Junshi Bioscience Co., Ltd.2

Indications

  • Cancer2
  • Non-Squamous Non-Small Cell Lung Cancer1
  • Lung Cancer1
  • Metastatic Colorectal Cancer1

Other2 trials

JS212 Combination Therapies in Metastatic Colorectal Cancer
Phase 2
Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.